SCHEMBL22472764

SCHEMBL22472764

Cc1cc(C)n2cnc(C(=O)NCCC3CCC(c4ccco4)CC3)c2n1

nearest known ligand 0.38

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SCD O00767 1/20 0.37
TSHR P16473 1/20 0.35
ALDH1A1 P00352 6/20 0.34
KDM4E B2RXH2 3/20 0.34
KMT2A Q03164 1/20 0.34
HPGD P15428 3/20 0.34
HSD17B10 Q99714 2/20 0.34
CACNA1B Q00975 1/20 0.34
APBA1 Q02410 1/20 0.34
CNR2 P34972 1/20 0.33
CHRM4 P08173 2/20 0.33
APOBEC3A P31941 1/20 0.33
MAPK1 P28482 1/20 0.33
DRD2 P14416 1/20 0.33
HTR2A P28223 1/20 0.33
DRD3 P35462 1/20 0.33
MAOB P27338 1/20 0.33
GAA P10253 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22472752 0.91 RIPK1 (0.37) SCDALDH1A1KDM4EKMT2AHPGD
SCHEMBL22472761 0.88 TSHR (0.36) SCDTSHRALDH1A1KMT2AHPGD
SCHEMBL23901595 0.86 CRHR1 (0.38) TSHRALDH1A1KDM4EKMT2AHSD17B10
SCHEMBL22472806 0.85 SCD (0.38) SCDTSHRALDH1A1KDM4EKMT2A
SCHEMBL23511968 0.85 SCD (0.40) SCDTSHRALDH1A1KDM4EKMT2A
SCHEMBL22767521 0.81 KDM4E (0.55) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL22472794 0.80 EGLN2 (0.36) SCDCNR2
SCHEMBL22472780 0.80 TDP1 (0.36) TSHRALDH1A1KDM4EKMT2AHPGD
SCHEMBL22472772 0.79 KDM4E (0.37) KDM4ECNR2
SCHEMBL22472743 0.78 ALDH1A1 (0.33) TSHRALDH1A1KDM4EKMT2AHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3215510-B1 SUBSTITUTED IMIDAZO[1,5-A]PYRIMIDINES AND THEIR USE IN THE TREATMENT OF MEDICAL DISORDERS BIAL R&D INVEST S A (PT) 2023-06-07 EP disclosed
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders LYSOSOMAL THERAPEUTICS INC. (US) 2020-09-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10786508-B2 Substituted imidazo[1,5-A]-pyrimidines and their use in the treatment of medical disorders GBA1, GAA, SNCA SCD 4094/4885TSHR 3497/4885ALDH1A1 1025/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.